Introduction {#j_jomb-2017-0030_s_001}
============

The von Hippel-Lindau tumor suppressor gene (*VHL*) is frequently mutated in sporadic form of clear-cell renal cell carcinoma (ccRCC) ([@j_jomb-2017-0030_ref_001], [@j_jomb-2017-0030_ref_002]). Inactivation of the *VHL* gene contributes to early phases of renal tumorigenesis by accummulation of hypoxia inducible factors (HIFs) and deregulation of processes important for renal epithelial cell morphology ([@j_jomb-2017-0030_ref_003], [@j_jomb-2017-0030_ref_004]). Elevated activity of mammalian target of rapamycin (mTORC1/mTORC2) signaling pathways were noticed in different types of tumors including clear-cell renal carcinoma ([@j_jomb-2017-0030_ref_005], [@j_jomb-2017-0030_ref_006]). It is well known that mTORC1 controls cellular growth, proliferation and metabolism via its effector molecules p70S6K1 (Ribosomal protein S6 kinase beta-1) and eIF4E-BP1 (Eukaryotic Translation Initiation Factor 4E Binding Protein 1) and that it is under the control of AMPK (5' adenosine monophosphate-activated protein kinase) and REDD1 (Regulated in Development and DNA Damage Response 1) ([@j_jomb-2017-0030_ref_007], [@j_jomb-2017-0030_ref_008], [@j_jomb-2017-0030_ref_009], [@j_jomb-2017-0030_ref_010], [@j_jomb-2017-0030_ref_011], [@j_jomb-2017-0030_ref_012], [@j_jomb-2017-0030_ref_013], [@j_jomb-2017-0030_ref_014], [@j_jomb-2017-0030_ref_015]). Additionally, mTORC1 regulates ribosomal biogenesis and nucleolar size ([@j_jomb-2017-0030_ref_016]). The Fuhrman nuclear grading system, an independent prognostic predictor for ccRCC, is based on nucleolar prominence and can be used as an indicator of mTORC1 activity ([@j_jomb-2017-0030_ref_017]). It has been shown that cancer cells utilize glycolysis as the main metabolic pathway for energy production even under normoxic conditions ([@j_jomb-2017-0030_ref_018], [@j_jomb-2017-0030_ref_019], [@j_jomb-2017-0030_ref_020]). The role of these molecules in the regulation of pyruvate dehydrogenase kinases (PDKs) is not well defined in ccRCC. Many studies were focused on the PDK1 isoform in different carcinomas, but there is no information about the expression level of PDK3 isoform in ccRCCs ([@j_jomb-2017-0030_ref_021], [@j_jomb-2017-0030_ref_022], [@j_jomb-2017-0030_ref_023]).

In the present study, we evaluated the effect of *VHL* mutational status on the expression level of mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 proteins in ccRCC.

Material and Methods {#j_jomb-2017-0030_s_002}
====================

This study was performed on 37 tumor and corresponding healthy renal tissue samples obtained from patients who underwent nephrectomy due to unilateral kidney tumor without history of hereditary VHL syndrome. All the patients provided written informed consent for participation and the study received the permission from the local Research Ethics Committee. Tissues were sampled after surgery, immediately frozen in liquid nitrogen and stored at -- 80 °C until use. All tumors were classified as clear-cell renal cell carcinoma by the pathologist.

Protein isolation and Western blot {#j_jomb-2017-0030_s_002_s_001}
----------------------------------

Proteins were extracted from tumorous and corresponding healthy renal tissue. Thirty mg tissue samples were dissected, homogenized and lysed in RIPA buffer containing complete EDTA-free protease inhibitor cocktails (Roche Applied Science, Mannheim, Germany) and left on ice for one hour. Samples were sonicated three times for 30 s followed by cooling for one minute and stored for one hour on ice. Samples were centrifuged for 20 min, 11 000 rpm at 4 °C. Supernatants were pipetted into new tubes. Bio-Rad Protein Assay was used for measurement of protein concentration at 595 nm. Prior to SDS-PAGE separation, proteins suspension was mixed with loading and sample buffer (NuPAGE LDS Sample Buffer, NuPAGE Reducing Agent, Invitrogen Life Technologies, Grand Island, New York, USA), denatured for 10 min at 90 °C and loaded into precast 4--12% Bis-Tris or 3--8% Tris-acetate gels (Invitrogen Life Technologies, Grand Island, New York, USA), depending on the molecular weight of detected proteins. Separated proteins were blotted on nitrocellulose/PVDF membranes using wet electrotransfer devices. Membranes were blocked with 5% nonfat milk in 1XTBST containing 0.1% Tween 20 for one hour at room temperature and incubated in primary antibody in 1XTBST overnight at 4 °C. \[anti--mTOR (1:1000, 7C10, Cell Signaling Technology, Danvers, Massa chusetts, USA); anti--eIF4EBP1 (1:1000, ab2606, Abcam, Cambridge, UK); anti--AMPK (1:500, ab80039, Abcam, Cambridge, UK); anti--REDD1 (1:500, H-110: sc-67051, Santa Cruz Biotechnology, Dallas, Texas, USA); anti--PDK3 (1:1000, LS-C111083, Lifespan Biosciences, Seattle, Washington, USA); anti-b-actin (1:1000, ab3280, Abcam, Cambridge, UK)\] Then, membranes were washed in 1XPBST, probed with appropriate secondary HRP-conjugated anti-mouse or anti-rabbit antibody for 1.5 hours at room temperature and washed in PBST. Proteins were visualized by chemiluminescence (Lumi-lightPLUS Western Blotting kit, Roche Applied Science, Mannheim, Germany). After visualization, membranes were stripped with 0.2 mol/L NaOH, and reprobed with another primary antibody or anti-b-actin antibody. The intensities of immunoreactive bands were determined using ImageQuant 5.2 software (GE Healthcare, Little Chalfont, UK). Protein loading was normalized to b-actin ([@j_jomb-2017-0030_ref_024]).

Statistical analysis {#j_jomb-2017-0030_s_002_s_002}
--------------------

All data are presented as mean ± SE. Differences between tumorous and corresponding non-tumorous tissues were estimated using nonparametric Kruskal Wallis analysis of variance followed by Mann Whitney test or ANOVA with Bonferroni correction, depending on data distribution. Pearson's test was used to detect correlation between two variables. Stepwise multivariate analysis was used to determine causal relationships between variables. *P* value \< 0.05 was considered statistically significant. Statistical analyses were done using SPSS® 13.0, Inc., Chicago, Illinois, USA.

Results {#j_jomb-2017-0030_s_003}
=======

Tumor classification based on VHL gene mutational status {#j_jomb-2017-0030_s_003_s_001}
--------------------------------------------------------

We used tumor samples with known mutational status in the *VHL* gene previously reported by our group ([@j_jomb-2017-0030_ref_025]). Among 37 samples of ccRCCs, in 21 (56.8%) tumors biallelic inactivation of *VHL* gene was detected (intragenic mutation plus loss of heterozygosity on 3p locus), 10 (27.0%) tumors have shown monoallelic inactivation of *VHL* (mutation or LOH on 3p locus) and in 6 (16.2%) tumors no alterations in *VHL* were found (wt *VHL*). Also, mutations or LOH were not found in all corresponding non-tumorous tissues.

Tumors with wt *VHL* gene have shown significantly higher Fuhrman's nuclear grade (2.8 ± 0.2) in comparison to tumors with monoallelic (1.8 ± 0.2; *P* = 0.026) and biallelic (2.1 ± 0.2; *P* = 0.04) inactivation of the *VHL* gene.

Western Blot analyses: mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 in tumorous and corresponding non-tumorous tissue {#j_jomb-2017-0030_s_003_s_002}
---------------------------------------------------------------------------------------------------------------

Intensities of immunoreactive bands normalized to b-actin (expression level of examined proteins) are presented in *[Table I](#j_jomb-2017-0030_tab_001){ref-type="table"}*. Irrespectively of the *VHL* gene status, all tumorous tissues similarly expressed mTOR, eIF4EBP1, and AMPK proteins (*[Figure 1](#j_jomb-2017-0030_fig_001){ref-type="fig"}, [Figure 2](#j_jomb-2017-0030_fig_002){ref-type="fig"}, [Figure 3](#j_jomb-2017-0030_fig_003){ref-type="fig"}*). Only tumors with biallelic inactivation demonstrated lower mTOR and higher eIF4EBP1 expression in comparison to control tissue (*P* = 0.002 for both).

![Expression level of mTOR in ccRCCs and corresponding non-tumorous tissue samples. A) Western blot for mTOR in tumorous and non-tumorous tissue. B) Tumors with biallelic inactivation underexpressed mTOR in comparison to control tissue. There was no significant difference regarding *VHL* mutational status. WT, wild-type *VHL*; M/LOH, *VHL*-mutated or loss of heterozygosity of 3p locus; M+LOH, *VHL*-mutated and loss of heterozygosity of 3p locus; C, control renal tissue. (\*P = 0.002 vs. control)](jomb-37-031-g001){#j_jomb-2017-0030_fig_001}

![Expression level of eIF4EBP1 in ccRCCs and corresponding non-tumorous tissue samples. A) Western blot for eIF4EBP1 in tumorous and non-tumorous tissue. B) Tumors with biallelic inactivation underexpressed eIF4EBP1 in comparison to control tissue. Abundance of eIF4EBP1 was not influenced by *VHL* gene mutational status. WT, wild-type *VHL*; M/LOH, *VHL*-mutated or loss of heterozygosity of 3p locus; M+LOH, *VHL*-mutated and loss of heterozygosity of 3p locus; C, control renal tissue. (\*P = 0.002 vs. control)](jomb-37-031-g002){#j_jomb-2017-0030_fig_002}

![Expression level of AMPK in ccRCCs and corresponding non-tumorous tissue samples. A) Western blot for AMPK in tumorous and non-tumorous tissue. B) Similar expression of AMPK irrespectively of *VHL* gene mutational status. WT, wild-type *VHL*; M/LOH, *VHL*-mutated or loss of heterozygosity of 3p locus; M+LOH, *VHL*-mutated and loss of heterozygosity of 3p locus; C, control renal tissue](jomb-37-031-g003){#j_jomb-2017-0030_fig_003}

###### 

Expression level of mTOR, eIF4E-BP1, AMPK, REDD1 and PDK3 proteins in ccRCCs and control renal tissue.

  *VHL*   mTOR           eIF4E-BP1      AMPK          REDD1              PDK3
  ------- -------------- -------------- ------------- ------------------ ---------------
  WT      0.83 ± 0.45    0.85 ± 0.35    0.59 ± 0.30   0.37 ± 0.15        1.06 ± 0.3a,c
  M/LOH   0.41 ± 0.19    0.47 ± 0.17    0.39 ± 0.13   0.06 ± 0.03a,b,c   4.33 ± 3.79
  M+LOH   0.21 ± 0.06a   0.80 ± 0.12a   0.70 ± 0.18   0.45 ± 0.10a       0.32 ± 0.08
  C       0.50 ± 0.07    0.35 ± 0.05    0.50 ± 0.08   0.25 ± 0.05        0.36 ± 0.06

*P* \< 0.05 vs. C; ^b^P \< 0.05 vs. WT; ^c^P \< 0.05 vs. M+LOH; WT, wild-type *VHL*; M/LOH, *VHL*-mutated or loss of heterozygosity of 3p locus; M+LOH, *VHL*-mutated and loss of heterozygosity of 3p locus; C-control renal tissue.

Expression level of REDD1 protein is influenced by the *VHL* gene. Tumors with monoallelic inactivation of *VHL* underexpressed REDD1 in comparison to both wt tumors (*P* = 0.042) and tumors with biallelic gene inactivation (*P* \< 0.005) as well as to control tissue (*P* = 0.004). On the contrary, REDD1 expression in tumorous tissue with biallelic inactivation of *VHL* was higher than in control tissue (*P* = 0.008) (*[Figure 4](#j_jomb-2017-0030_fig_004){ref-type="fig"}*).

![REDD1 expression level in ccRCCs and corresponding non-tumorous tissue samples. A) Western blot for REDD1 in tumorous and non-tumorous tissue. B) Tumors with monoallelic inactivation of *VHL* underexpressed REDD1 in comparison to wtVHL and tumors with biallelic inactivation of VHL, and to control renal tissue. REDD1 expression was higher in tumors with biallelic *VHL* inactivation than in control tissue. WT, wild-type *VHL*; M/LOH, *VHL*-mutated or loss of heterozygosity of 3p locus; M+LOH, *VHL*-mutated and loss of heterozygosity of 3p locus; C, control renal tissue. (\*P \< 0.001 vs. control, ^\#^P = 0.042 vs. wt*VHL*; ^‡^P \< 0.005 vs. M+LOH)](jomb-37-031-g004){#j_jomb-2017-0030_fig_004}

Wild-type ccRCCs expressed significantly higher amounts of PDK3 protein in comparison to tumors with biallelic inactivation of the *VHL* gene (*P* = 0.012) and control renal tissue (*P* = 0.016) (*[Figure 5](#j_jomb-2017-0030_fig_005){ref-type="fig"}*).

![Expression level of PDK3 in ccRCCs and corresponding non-tumorous tissue samples. A) Western blot for PDK3 in tumorous and non-tumorous tissue. B) wt *VHL* tumors expressed higher amounts of PDK3 in comparison to tumors with biallelic *VHL* inactivation and to control tissue. WT, wild-type *VHL*; M/LOH, *VHL*-mutated or loss of heterozygosity of 3p locus; M+LOH, *VHL*-mutated and loss of heterozygosity of 3p locus; C, control renal tissue. (\*P = 0.016 vs. control; \#P = 0.012 vs. M+LOH)](jomb-37-031-g005){#j_jomb-2017-0030_fig_005}

Correlations and multivariate linear regression analysis {#j_jomb-2017-0030_s_003_s_003}
--------------------------------------------------------

In tumors with wt *VHL* gene expression of PDK3 protein was in a positive correlation with AMPK protein (r = 0.987, *P* = 0.013). Multivariate linear regression analysis has shown that 97.4% of variability in the expression level of PDK3 can be explained by

variations in AMPK expression (Coefficient B ± SE, 0.778 ± 0.09, *P* \< 0.001).

Discussion {#j_jomb-2017-0030_s_004}
==========

Tumors with biallelic *VHL* gene inactivation exhibited higher expression levels of REDD1 than those with monoallelic *VHL* inactivation and corresponding control tissues. While mTOR expression was similar among tumor tissues, it was lower in tissues with biallelic inactivation than in controls. We also demonstrated that biallelic inactivation is accompanied with lower Fuhrman's grade in comparison to wt ccRCCs. This is in line with the results of Kucejova et al. ([@j_jomb-2017-0030_ref_016]) who demonstrated that *VHL* gene inactivation is crucial for REDD1 overexpression. They also provide the evidence for the presence of a positive relation between Fuhrman's grade and mTORC1 activity. Thus, underexpression of mTOR with upregulation of REDD1 suggests dominant signaling through mTORC2. This could be supported by the presence of HIF-2a in *VHL* negative tumorous tissues, whose synthesis is hinged on mTORC2 activity ([@j_jomb-2017-0030_ref_026]). Further-more, these tumors have increased expression levels of eIF4EBP1 in comparison to corresponding healthy tissues. It has been shown that both hypo phosphorylation of eIF4EBP1 and overexpression of *eIF4EBP1* as a cell-protective mechanism in stress conditions inhibit mTORC1 activity and restrain protein synthesis ([@j_jomb-2017-0030_ref_027]). The interplay between eIF4EBP1 and mTORC1 during energy deprivation appears to be the consequence of REDD1 overexpression in *VHL* negative tumors, indicating that balancing between mTORC1 and mTORC2 could depend on pVHL ([@j_jomb-2017-0030_ref_028]).

Similar expression levels of REDD1 in wt *VHL* and tumors with biallelic inactivation of *VHL* may indicate functional inactivation of pVHL rendered by hypoxia ([@j_jomb-2017-0030_ref_029], [@j_jomb-2017-0030_ref_030], [@j_jomb-2017-0030_ref_031]). Higher Fuhrman's grade in wt *VHL* tumors than in tumors with biallelic inactivation of *VHL* accompanied with similar expressions of REDD1 and mTOR may reflect resistance of mTORC1 to REDD1 inhibition ([@j_jomb-2017-0030_ref_016], [@j_jomb-2017-0030_ref_032]).

Along with incapability to increase REDD1 expression, VHL haploinsufficient tumors exhibited unexpectedly decreased levels of the aforementioned REDD1. In spite of the proposed regulation of HIFs by negative feedback control ([@j_jomb-2017-0030_ref_033]), our results suggest that decreased levels of REDD1 in tumors with monoallelic inactivation of *VHL* are not only transcriptionally regulated by the HIFs whose expression is *VHL* independent ([@j_jomb-2017-0030_ref_034]). Possible explanations for the depletion of REDD1 could be the presence of Redd1 mutations, which are apparently rare ([@j_jomb-2017-0030_ref_016]). Additionally, it was reported that miR-221 which binds to 3'-UTR of *Redd1* transcript is overexpressed in patients with ccRCCs ([@j_jomb-2017-0030_ref_035], [@j_jomb-2017-0030_ref_036], [@j_jomb-2017-0030_ref_037], [@j_jomb-2017-0030_ref_038]). Besides, tumorous expression of REDD1 and TSC1 (Hamartin) follows the same pattern of expression and *VHL* dependency ([@j_jomb-2017-0030_ref_025]). Of note is that REDD1, TSC1 and TSC2 (Tuberin) degradation is regulated by the mutual ubiquitin-dependent proteasomal system comprised of CUL4A-DDB1-ROC1-b-TRCP E3 ligase complex mediated by phosphorylation activity of GSK3b (Glycogen Synthase Kinase 3b) ([@j_jomb-2017-0030_ref_039], [@j_jomb-2017-0030_ref_040]). Potential link between the expression of REDD1 and TSC1 in ccRCC could be GSK3b since it is also involved in pVHL phosphorylation that affects its HIF-independent functions ([@j_jomb-2017-0030_ref_032], [@j_jomb-2017-0030_ref_041], [@j_jomb-2017-0030_ref_042]).

Results of our study also implicate that the meta bolic profile of ccRCCs depends on the *VHL* mutational status. Expression of PDK3 in wt*VHL* tumors was higher in comparison to tumors with biallelic inactivation of *VHL* and corresponding control tissue. Over expression of PDK3 in wt *VHL* tumors suggests glycolysis as a dominant metabolic pathway for ATP production. This finding highlights the importance of determination of *VHL* mutational status for the most efficient therapeutic strategy ([@j_jomb-2017-0030_ref_043]). Almost all (97.4%) variability in PDK3 expression is explained by the amount of AMPK in these tumors reflecting a positive functional relation between the two molecules in response to hypoxia ([@j_jomb-2017-0030_ref_044]).

Although small sample size was a limitation of the present study, significant differences in the expression profile of wt*VHL* and tumors with biallelic inactivation of *VHL* may provide advantages in the therapy of ccRCC and should be considered for further investigation.

In conclusion, expressions of mTOR, eIF4EBP1 and AMPK proteins were *VHL* independent in ccRCC. Our study provides additional evidence that *VHL* mutational status affects REDD1 expression in these tumors. For the first time, we have shown that PDK3 has *VHL* dependent expression in sporadic ccRCC.
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C

:   control renal tissue;

M/LOH

:   VHL-mutated or loss of heterozygosity of 3p locus;

M+LOH

:   VHL-mutated and loss of heterozygosity of 3p locus;

WT

:   wild-type VHL.
